AptarGroup, Inc. (ATR) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

Earnings Reports

• Aptar (ATR) Q2 2026: Pharma Ex-Emergency Grows 8%, Margin Recovery Signals Inflection
  July 31, 2026
• Aptar (ATR) Q4 2025: Tooling Sales Hit Decade High, Margin Headwinds Set Stage for 2026 Reset
  June 15, 2026
• APTAR (ATR) Q1 2026: Emergency Medicine Down $65M, Margin Compression Drives Cautious Optimism
  May 01, 2026
• Aptar (ATR) Q3 2025: Emergency Medicine Set for 35% Decline, Margin Mix Faces Reset
  October 31, 2025
• APTAR (ATR) Q2 2025: Pharma Margin Rises 130bps as Injectables and Active Materials Offset Emergency Med Slowdown
  August 01, 2025
• Aptar (ATR) Q1 2025: EBITDA Margin Expands 120bps as Pharma and Beauty Pipelines Reaccelerate
  July 06, 2025
• Aptar (ATR) Q3 2024: Pharma Royalty Revenue Grows, Margins Hit 23% High as Closures Rebounds
  October 25, 2024
• Aptar (ATR) Q2 2024: Pharma Drives 7% Segment Growth as Beauty Normalizes and Capex Peaks
  July 26, 2024
• APTAR (ATR) Q1 2024: Pharma Core Sales Up 13% as Proprietary Drug Delivery Drives Structural Margin Gains
  April 26, 2024
• Aptar (ATR) Q4 2023: Pharma Core Sales Up 11% as Margin Expansion Drives Double-Digit EPS Growth
  February 09, 2024

Browse all companies